MDACC Study No:2012-1105(2011-0554SOLIDTUM) ( NCT No: NCT01461538)
Title:Screening protocol to detect tumor antigen expression required for enrollment on clinical research protocols of antibody-directed therapy
Principal Investigator:Jorge Cortes
Treatment Agent:Brentuximab Vedotin
Study Status:Closed
Study Description:The goal of this pre-screening study is to learn if the tumor tissue has a
tumor marker called CD30. Tumor markers may be related to the status of the
disease. Researchers think that having CD30 may mean that the cancer is more
likely to respond to the study drug, ADCETRIS™(brentuximab vedotin). This is
the pre-screening study for a clinical research study where brentuximab vedotin
is given.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:N/A
Treatment Agents:Brentuximab Vedotin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Seattle Genetics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults